Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 71, Issue 5-6, 1999, Pages 181-189

  Lichtner, R B ^a   Parczyk, K ^a   Birchmeier, W ^b   Schneider, M R ^a  

^a BAYER PHARMA AG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CELL GROWTH; HUMAN; HUMAN CELL; MITOGENESIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL DIVISION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEUREGULIN-1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033489849     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00136-3     Document Type: Article

References (52)

1. Howell A., DeFriend D., Anderson E. Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Reviews on Endocrine-Related Cancer. 43:1993;5-12.
2. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promotor-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal. 9:1990;2811-2818.
3. Wakeling A.E. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research. 54:1994;408-414.
4. Howell A., DeFriend D.J., Robertson J.F.R., Blamey R.W., Anderson L., Sutcliffe F.A., Walton P. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. British Journal of Cancer. 74:1996;300-308.
5. Dickson R.B., Lippman M.E. Autocrine and paracrine growth factors in the normal and the neoplastic breast. Harris, Lippman, Morrow, Hellman. Diseases of the Breast. 1996;272-283 Raven, Lippincott.
6. Vignon F., Bouton M.-M., Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochemical and Biophysical Research Communication. 146:1987;1502-1508.
7. Koga M., Sutherland R.L. Epidermal growth factor partially reverses the inhibitory effects of antiestrogens on T47D human breast cancer cell growth. Biochemical and Biophysical Research Communication. 146:1987;739-745.
8. Wakeling A.E. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. The Journal of Steroid Biochemistry. 34:1989;183-188.
9. Wakeling A.E., Newboult E., Peters S.W. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. The Journal of Molecular Endocrinology. 2:1989;225-234.
10. Freiss G., Rochefort H., Vignon F. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochemical and Biophysical Research Communication. 173:1990;919-926.
11. Ignar-Trowbridge D.M., Nelson K.G., Bidwell M.C., Curtis S.W., Washburn T.F., McLachlan J.A., Korach S.K. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proceedings of the National Academy of Science USA. 89:1992;4658-4662.
12. Aronica S.M., Katzenellenbogen B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology. 7:1993;743-752.
13. Ma Z.Q., Santagati S., Patrone C., Pollio G., Vegeto E., Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Molecular Endocrinology. 8:1994;910-918.
14. Newton C.J., Buric R., Trapp T., Brockmeier S., Pagotto U., Stalla G.K. The unliganded estrogen receptor (ER) transduces growth factor signals. The Journal of Steroid Biochemistry and Molecular Biology. 48:1994;481-486.
15. Hafner F., Holler E., von Angerer E. Effect of growth factors on estrogen receptor mediated gene expression. The Journal of Steroid Biochemistry and Molecular Biology. 58:1996;385-393.
16. Grunt T.W., Saceda M., Martin M.B., Lupu R., Dittrich E., Krupitza G., Harant H., Huber H., Dittrich C. Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. The International Journal of Cancer. 63:1995;560-567.
17. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., Gorman C.M., Parker M.G., Sliwkowski M.X., Slamon D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446.
18. Niemann C., Brinkmann V., Spitzer E., Hartmann G., Sachs M., Naundorf H., Birchmeier W. Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. Journal of Cell Biology. 143:1998;533-545.
19. Kueng W., Silber E., Eppenberger U. Quantification of cells cultured on 96-well plates. Analytical Biochemistry. 182:1989;6-19.
20. Murphy L.D. Antiestrogen action and growth factor regulation. Breast Cancer Research and Treatment. 31:1994;61-71.
21. Earp H.S., Dawson T.L., Li X., Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Research and Treatment. 35:1995;115-132.
22. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Science USA. 89:1992;4037-4041.
23. DeFriend J., Howell A., Nicholson R.I., Anderson E., Dowsett M., Mansel R.E., et al. Estrogen receptor phosphorylation. The Journal of Biological Chemistry. 267:1992;7263-7268.
24. Castoria G., Migliaccio A., Green S., DiDomenico M., Chambon P., Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry. 32:1993;1740-1750.
25. Kato S., Endoh H., Masuhiro Y., Kitamo T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Metzger D., Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
26. Bunone G., Briand P.-A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal. 15:1996;2174-2183.
27. Arnold S.F., Vorojeikina D.P., Notides A.C. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. The Journal of Biological Chemistry. 270:1995;30205-30212.
28. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal. 15:1996;1292-1300.
29. Guvakova M.A., Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Research. 57:1997;2606-2610.
30. Cullen K.J., Yee D., Sly W.S., et al. Insulin-like growth factor expression and function in human breast cancer. Cancer Research. 50:1990;48-53.
31. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Research and Treatment. 32:1994;85-95.
32. Stewart A.J., Johnson M.D., May F.E.B., Westley B.R. Role of insulin-like growth factors and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. The Journal of Biological Chemistry. 265:1990;21172-21178.
33. Huynh H., Nickerson T., Pollak M., Yang X. Regulation of insulin-like growth factor I receptor by the pure antiestrogen ICI 182780. Clinical Cancer Research. 2:1996;2037-2042.
34. deCupis A., Favoni R.E. Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens. TIPS. 18:1997;245-251.
35. Pekonen F., Partanen S., Mäkinen T., Rutanen E.-M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Research. 48:1988;1343-1347.
36. Huynh H.T., Yang X., Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. The Journal of Biological Chemistry. 271:1996;1016-1021.
37. Huynh H., Yang X.-F., Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth and Differentiation. 7:1996;1501-1506.
38. Mohan S., Nakao Y., Honda Y., Landale E., Leser U., Dony C., Lang K., Baylink D.J. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. The Journal of Biological Chemistry. 270:1995;20424-20431.
39. Van den Berg H.W., Claffie D., Boylan M., McKillen J., Lynch M., McKibben B. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. British Journal of Cancer. 73:1996;477-481.
40. Daly R.J., Harris W.H., Wang D.Y., Darbre P.D. Autocrine production of insulin growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth and Differentation. 2:1991;457-464.
41. Holmes W.E., Sliwkowski M.X., Akita R.W., Henzel W.J., Lee J., Park J.W., Yansura D., Abadi N., Raab H., Lewis G.D., Shepard H.M., Kuang W.-J., Wood W.I., Goeddel D.V., Vandlen R.L. Identification of heregulin, a specific activator of p185erbB2. Science. 256:1992;1205-1210.
42. Siegall C.B., Bacus S.S., Cohen B.D., Plowman G.D., Mixan B., Chace D., Chin D.M., Goetze A., Green J.M., Hellström I., Hellström K.E., Fell H.P. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. The Journal of Biological Chemistry. 270:1995;7625-7630.
43. Graus-Porta D., Beerli R.R., Daly J., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO Journal. 16:1997;1647-1655.
44. Read L.D., Keith D. Jr, Slamon D.J., Katzenellenbogen B.S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Research. 50:1990;3947-3951.
45. Dati C., Antoniotti S., Taverna D., Perroteau I., DeBertoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene. 5:1990;1001-1006.
46. Antoniotti S., Maggiora P., Dati C., De Bortoli M. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. European Journal of Cancer. 28:1992;318-321.
47. Wright C., Nicholson S., Angus B., Sainsbury J.R.C., Farndon J., Cairns J., Harris A.L., Horne C.H.W. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer. 65:1992;118-121.
48. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., Shepard M., Osborne C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment. 24:1995;85-95.
49. Liu Y., El-Ashry D., Chen D., Ding I.Y.F., Kern F.G. MCF-7 breast cancer cells overexpressing transfected c-erb B-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment. 34:1995;97-117.
50. Lupu R., Cardillo M., Cho C., Harris L., Hijazi M., Perez C., Rosenberg K., Yang D., Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research and Treatment. 38:1996;57-66.
51. Lupu R., Lippman M.E. The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Research and Treatment. 27:1993;83-93.
52. Witters L.M., Kumar R., Chinchilli V.M., Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Research and Treatment. 42:1997;1-5.